Wells Fargo analyst Larry Biegelsen downgraded Novocure (NVCR) to Equal Weight from Overweight with a price target of $14.50, down from $40.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCR: